REG - GlaxoSmithKline PLC - Director/PDMR Shareholding
12/04/2022 16:00
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220412:nRSL1656Ia&default-theme=true
RNS Number : 1656I GlaxoSmithKline PLC 12 April 2022
GlaxoSmithKline plc (the 'Company')
Transaction notification
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Ms E Walmsley
b) Position/status Chief Executive Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GlaxoSmithKline plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b) Nature of the transaction Increase in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 7 April 2022 on Ordinary Shares held in
the Company's Deferred Annual Bonus Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£17.4100 956
£17.4100 768
£17.4100 639
d) Aggregated information
Aggregated volume Price 2,363
£17.4100
e) Date of the transaction 2022-04-08
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Mr I Mackay
b) Position/status Chief Financial Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GlaxoSmithKline plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b) Nature of the transaction Increase in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 7 April 2022 on Ordinary Shares held in
the Company's Deferred Annual Bonus Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£17.4100 661
£17.4100 518
£17.4100 443
d) Aggregated information
Aggregated volume Price 1,622
£17.4100
e) Date of the transaction 2022-04-08
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Dr H Barron
b) Position/status Chief Scientific Officer and President, R&D
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GlaxoSmithKline plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument American Depositary Shares ('ADSs')
ISIN: US37733W1053
b) Nature of the transaction Increase in notional interest in ADSs following the re-investment of dividends
paid to shareholders on 7 April 2022 on ADSs held in the Company's Deferred
Annual Bonus Plan
c) Price(s) and volume(s) Price(s) Volume(s)
$46.2300 523
$46.2300 437
$46.2300 331
d) Aggregated information
Aggregated volume Price 1,291
$46.2300
e) Date of the transaction 2022-04-08
f) Place of the transaction New York Stock Exchange (XNYS)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Mr R Connor
b) Position/status President, Vaccines and Global Health
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GlaxoSmithKline plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b) Nature of the transaction Increase in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 7 April 2022 on Ordinary Shares held in
the Company's Deferred Annual Bonus Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£17.4100 162
£17.4100 242
£17.4100 140
d) Aggregated information
Aggregated volume Price 544
£17.4100
e) Date of the transaction 2022-04-08
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Ms D Conrad
b) Position/status Chief People Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GlaxoSmithKline plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b) Nature of the transaction Increase in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 7 April 2022 on Ordinary Shares held in
the Company's Deferred Annual Bonus Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£17.4100 150
£17.4100 99
£17.4100 92
d) Aggregated information
Aggregated volume Price 341
£17.4100
e) Date of the transaction 2022-04-08
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Mr J Ford
b) Position/status SVP and Group General Counsel, Legal and Compliance
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GlaxoSmithKline plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b) Nature of the transaction Increase in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 7 April 2022 on Ordinary Shares held in
the Company's Deferred Annual Bonus Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£17.4100 184
£17.4100 142
£17.4100 111
d) Aggregated information
Aggregated volume Price 437
£17.4100
e) Date of the transaction 2022-04-08
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Ms S Jackson
b) Position/status SVP, Global Communications and CEO Office
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GlaxoSmithKline plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b) Nature of the transaction Increase in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 7 April 2022 on Ordinary Shares held in
the Company's Deferred Annual Bonus Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£17.4100 86
£17.4100 60
£17.4100 56
d) Aggregated information
Aggregated volume Price 202
£17.4100
e) Date of the transaction 2022-04-08
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Mr B McNamara
b) Position/status CEO, GSK Consumer Healthcare
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GlaxoSmithKline plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument American Depositary Shares ('ADSs')
ISIN: US37733W1053
b) Nature of the transaction Increase in notional interest in ADSs following the re-investment of dividends
paid to shareholders on 7 April 2022 on ADSs held in the Company's Deferred
Annual Bonus Plan
c) Price(s) and volume(s) Price(s) Volume(s)
$46.2300 55
$46.2300 80
$46.2300 101
d) Aggregated information
Aggregated volume Price 236
$46.2300
e) Date of the transaction 2022-04-08
f) Place of the transaction New York Stock Exchange (XNYS)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Mr L Miels
b) Position/status Chief Commercial Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GlaxoSmithKline plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b) Nature of the transaction Increase in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 7 April 2022 on Ordinary Shares held in
the Company's Deferred Annual Bonus Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£17.4100 314
£17.4100 232
£17.4100 173
d) Aggregated information
Aggregated volume Price 719
£17.4100
e) Date of the transaction 2022-04-08
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Ms S Ramakrishnan
b) Position/status Chief Digital and Technology Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GlaxoSmithKline plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument American Depositary Shares ('ADSs')
ISIN: US37733W1053
b) Nature of the transaction Increase in notional interest in ADSs following the re-investment of dividends
paid to shareholders on 7 April 2022 on ADSs held in the Company's Deferred
Annual Bonus Plan
c) Price(s) and volume(s) Price(s) Volume(s)
$46.2300 31
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2022-04-08
f) Place of the transaction New York Stock Exchange (XNYS)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Mr D Redfern
b) Position/status Chief Strategy Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GlaxoSmithKline plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b) Nature of the transaction Increase in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 7 April 2022 on Ordinary Shares held in
the Company's Deferred Annual Bonus Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£17.4100 208
£17.4100 170
£17.4100 136
d) Aggregated information
Aggregated volume Price 514
£17.4100
e) Date of the transaction 2022-04-08
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Mr R Simard
b) Position/status President, Pharmaceuticals Supply Chain
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GlaxoSmithKline plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b) Nature of the transaction Increase in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 7 April 2022 on Ordinary Shares held in
the Company's Deferred Annual Bonus Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£17.4100 189
£17.4100 120
£17.4100 102
d) Aggregated information
Aggregated volume Price 411
£17.4100
e) Date of the transaction 2022-04-08
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Mr P Thomson
b) Position/status President, Global Affairs
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GlaxoSmithKline plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b) Nature of the transaction Increase in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 7 April 2022 on Ordinary Shares held in
the Company's Deferred Annual Bonus Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£17.4100 131
£17.4100 98
£17.4100 79
d) Aggregated information
Aggregated volume Price 308
£17.4100
e) Date of the transaction 2022-04-08
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Ms D Waterhouse
b) Position/status CEO, ViiV Healthcare
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GlaxoSmithKline plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b) Nature of the transaction Increase in notional interest in Ordinary Shares following the re-investment
of dividends paid to shareholders on 7 April 2022 on Ordinary Shares held in
the Company's Deferred Annual Bonus Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£17.4100 138
£17.4100 163
d) Aggregated information
Aggregated volume Price 301
£17.4100
e) Date of the transaction 2022-04-08
f) Place of the transaction London Stock Exchange (XLON)
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END DSHZLLFFLZLZBBLRecent news on GSK
See all newsREG - GSK PLC - Transaction in Own Shares
AnnouncementREG - GSK PLC - Exdensur (depemokimab ulla) approved by US FDA
AnnouncementREG - GSK PLC - Transaction in Own Shares
AnnouncementREG - GSK PLC - Exdensur (depemokimab) UK MHRA approval
AnnouncementREG - GSK PLC - Transaction in Own Shares
Announcement